The Lancet

Elsevier BV · General Science & Medicine · ISSN 0140-6736

Impact (2-yr): 21.3
h-index: 1.2K
Open access: 14%
Works: 475.7K
Papers this month: 128

Track Lancet in JClubFree on iPhone and Android · in the app, the list is My Journals

Rebuilt 23 October 2026 at 9:26 am AEDT

Moved this week

Everything that moved →

[(177)Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.
The Lancet · 29 Aug 2026 · Randomized Controlled Trial
Read the AI summary in JClub
- 2 cited this week
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42561994
Open in JClub
Strengthening health systems to prioritise, provide care, and prevent osteoarthritis: a roadmap for global health policy.
The Lancet · 11 Oct 2026 · Review
Global health policy can significantly reduce the burden of osteoarthritis by implementing a strategic roadmap focused on recognition, care, and prevention for the nearly 600 million affected individuals.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42860133
Open in JClub

Latest in Lancet

Newest first · last 60 days

Roger Detels.
The Lancet · 17 Oct 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42880298
Open in JClub
8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.
The Lancet · 17 Oct 2026 · Multicenter Study
An 8-week sofosbuvir-velpatasvir regimen is non-inferior to 12 weeks in achieving SVR12 in non-cirrhotic, treatment-naive HCV patients in India.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42815507
Open in JClub
WHO should adjust its cervical cancer plan - Authors' reply.
The Lancet · 17 Oct 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42880300
Open in JClub
Shortening treatment to accelerate hepatitis C elimination.
The Lancet · 17 Oct 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42880296
Open in JClub
Making every vial count: fractional dosing of yellow fever vaccine.
The Lancet · 17 Oct 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42880295
Open in JClub
Addressing threats to future global health-what is the right timeframe?
The Lancet · 17 Oct 2026 · Review
Applying population ethics to future health raises complex questions about how far into the future concerns should extend beyond the 21st century.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42858756
Open in JClub
Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes.
The Lancet · 17 Oct 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42880294
Open in JClub
Rethinking threats to human survival.
The Lancet · 17 Oct 2026 · Editorial
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42860132
Open in JClub
The WHS Academic Alliance-Lancet Commission on academic responsibility for trust in science and societal change.
The Lancet · 17 Oct 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42716073
Open in JClub
Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.
The Lancet · 17 Oct 2026 · Randomized Controlled Trial
Orforglipron demonstrates non-inferiority to insulin glargine for major adverse cardiovascular events in adults with type 2 diabetes at increased cardiovascular risk, with a hazard ratio of 0.84 (95% CI 0.59-1.20).
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42815506
Open in JClub
Immunogenicity of fractional one-fifth and one-half doses of 17DD yellow fever vaccine compared with full dose in children aged 9-23 months in Uganda: a phase 4, single-blind, randomised clinical trial.
The Lancet · 17 Oct 2026 · Randomized Controlled Trial
Fractional doses of 17DD yellow fever vaccine in children aged 9-23 months are non-inferior to full doses in inducing initial seroconversion, with no significant difference between doses.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42727590
Open in JClub
Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet · 17 Oct 2026 · Randomized Controlled Trial
Garetosmab significantly reduces new heterotopic bone lesions in adults with fibrodysplasia ossificans progressiva, with a rate ratio of 0.06 at 3 mg/kg and 0.10 at 10 mg/kg.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42805227
Open in JClub
Bundibugyo virus: coordinating a cross-border response.
The Lancet · 17 Oct 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42849493
Open in JClub
WHO should adjust its cervical cancer plan.
The Lancet · 17 Oct 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42880299
Open in JClub
A novel and effective treatment for fibrodysplasia ossificans progressiva.
The Lancet · 17 Oct 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42805228
Open in JClub
Smoking rates: when should harm-reduction evidence be updated?
The Lancet · 17 Oct 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42880302
Open in JClub
Cultural calibration is needed in global mental disorder burden estimates - Authors' reply.
The Lancet · 17 Oct 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42880306
Open in JClub
John Wong: making an impact on population health at scale.
The Lancet · 17 Oct 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42858753
Open in JClub
Smoking rates: when should harm-reduction evidence be updated? - Authors' reply.
The Lancet · 17 Oct 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42880301
Open in JClub
Underuse of neuromodulation in depression care - Authors' reply.
The Lancet · 17 Oct 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42880304
Open in JClub
Department of Error.
The Lancet · 17 Oct 2026 · Published Erratum
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42880308
Open in JClub
Cultural calibration is needed in global mental disorder burden estimates.
The Lancet · 17 Oct 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42880305
Open in JClub
Department of Error.
The Lancet · 17 Oct 2026 · Published Erratum
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42880309
Open in JClub
Optimising standard of care in non-small-cell lung cancer trials - Authors' reply.
The Lancet · 17 Oct 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42880310
Open in JClub
Offline: In praise of astrologers, sorcerers, and magicians.
The Lancet · 17 Oct 2026 · Editorial
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42880297
Open in JClub
Underuse of neuromodulation in depression care.
The Lancet · 17 Oct 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42880303
Open in JClub
21st century global threats to health are not what you think.
The Lancet · 17 Oct 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42858754
Open in JClub
The Lancet Commission on 21st century global threats to health.
The Lancet · 17 Oct 2026 · Review
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42858757
Open in JClub
Optimising standard of care in non-small-cell lung cancer trials.
The Lancet · 17 Oct 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42880307
Open in JClub
Health care criminalised in Italian immigration detention centres.
The Lancet · 16 Oct 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42887510
Open in JClub

Track Lancet in JClub

Journals this month

All journals →

Topics moving, week to 22 Oct 2026

All topics →

By field

All journals by field →

Moved this week

Latest in Lancet

Browse JClub